13F-HR filed by Sanofi
Sanofi filed this 13F-HR for the quarter ended 2024-12-31, filed 2025-02-14, with 9 holding rows worth $174,360,245.
- Accession
- 0000950123-25-002465
- Filer
- CIK 1121404
- Filed
- 2025-02-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2024
A holdings report, 9 entries on the cover page, a total value of $174,360,245 stated on the cover page (in dollars after the unit check, H1), rows summing to $174,360,245 with VALUE read as dollars as filed, 13F file number 028-25202. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| MEIRAGTX HOLDINGS PLC | G59665102 | COMMON STOCK | 12,197,737 | $74,284,218 | dollars as filed | |
| NOVAVAX INC | 670002401 | COM NEW | 6,880,481 | $55,319,067 | dollars as filed | |
| INHIBRX BIOSCIENCES INC | 45720N103 | COM | 1,157,926 | $17,832,060 | dollars as filed | |
| ANAPTYSBIO INC | 032724106 | COM | 821,917 | $10,882,181 | dollars as filed | |
| IGM BIOSCIENCES INC | 449585108 | COM | 1,438,975 | $8,792,137 | dollars as filed | |
| ELEDON PHARMACEUTICALS INC | 28617k101 | COM | 814,980 | $3,357,718 | dollars as filed | |
| LAVA THERAPEUTICS NV | N51517105 | SHS | 1,919,455 | $1,825,402 | dollars as filed | |
| INOZYME PHARMA INC | 45790W108 | COM | 443,255 | $1,227,816 | dollars as filed | |
| Q32 BIO INC | 746964105 | Common Stock | 244,083 | $839,646 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0000950123-25-002465 | this filing | 2025-02-14 | acceptance time not in the bulk data set |